Global Cardiovascular Drugs Market to Reach $124.9 Billion by 2030
The global market for Cardiovascular Drugs estimated at US$95.2 Billion in the year 2022, is projected to reach a revised size of US$124.9 Billion by 2030, growing at a CAGR of 3.4% over the analysis period 2022-2030. Anticoagulants, one of the segments analyzed in the report, is projected to record a 4% CAGR and reach US$57.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Antihypertensive segment is readjusted to a revised 3% CAGR for the next 8-year period.The U.S. Market is Estimated at $25.9 Billion, While China is Forecast to Grow at 5.9% CAGR
The Cardiovascular Drugs market in the U.S. is estimated at US$25.9 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$25.3 Billion by the year 2030 trailing a CAGR of 5.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.8% and 2.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$16.3 Billion by the year 2030.Select Competitors (Total 113 Featured) -
- Abbott Laboratories, Inc.
- Astellas Pharma US, Inc.
- AstraZeneca PLC
- Bayer AG
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Gilead Sciences, Inc.
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis International AG
- Otsuka Pharmaceutical Co., Ltd.
- Pfizer, Inc.
- Sanofi-aventis U.S. LLC
- Takeda Pharmaceutical Co., Ltd.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories, Inc.
- Astellas Pharma US, Inc.
- AstraZeneca PLC
- Bayer AG
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Gilead Sciences, Inc.
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis International AG
- Otsuka Pharmaceutical Co., Ltd.
- Pfizer, Inc.
- Sanofi-aventis U.S. LLC
- Takeda Pharmaceutical Co., Ltd.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 413 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 95.2 Billion |
Forecasted Market Value ( USD | $ 124.9 Billion |
Compound Annual Growth Rate | 3.5% |
Regions Covered | Global |